



GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL
ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi – 110002
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

File No. CT/22/000078

To

M/s. Star Genomics India Private Limited,
House No. 3 Thorn Hill Road, Civil Lines,
Allahabad – 211001, Uttar Pradesh, India.
Tel. No.: 011-40651001, Fax: 011-40651001
E-Mail: raman.dugal@starhealthnetwork.com

Sir,

With reference to your application no. GCT/CT04/FF/2022/33350 (GCT/78/22) dated 10-AUG-2022, please find enclosed herewith the permission in Form CT-06 for conduct of phase 2 clinical trial titled, **“A Phase 2 Open-Label Basket Study of FS118, a LAG-3/PD-L1 Bispecific Antibody, in Subjects with Advanced and Early-Stage Malignancies”** vide study protocol no.: **FS118-21201, Version 2.0 dated 15-MAR-2022** with a total of up-to 30 subjects under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, specifically that: -

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

- (iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) Where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

- (xv) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study data generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;
- (xix) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

RAJEEV SINGH
(Dr. Rajeev Singh Raghuvanshi)
RAGHUVANSHI
Central Licensing Authority
HI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD
CONTROL ORGANIZATION, ou=RAJEEV SINGH
RAGHUVANSHI, email=rajeev.singh@cdso
2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c276
SerialNumber=557F5E7D0419820003BDC902D0
ETFE73CFA12A1A26EA94FA5701124A19013,
cn=RAJEEV SINGH RAGHUVANSHI
Date: 2023.03.03 16:48:19 +05'30"

(See rules 22,25,26,29 and 30)

Dr. Rajeev Singh Raghuvanshi
Drugs Controller, General (India)

Digitally signed by RAJEEV SINGH
RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD
CONTROL ORGANIZATION, ou=RAJEEV SINGH
RAGHUVANSHI
1.2.84.20=80k63a2e3e4edf0eb2a35774cde603
22699a1015e06564e6754b7e5d1cb,
postalCode=800035, st=JHARKHAND,
serialNumber=65755472940985D803BD9C
020E1E3B312A74092A454F70112A41
9013, cn=RAJEEV SINGH RAGHUVANSHI
2023.03.03 16:48:36 +05'30'

Names of the new drug or investigational new drug	FS118 (IgG1 bispecific human monoclonal antibody construct (mAb2) that binds both LAG-3 and PD-L1)
Therapeutic class:	Anticancer
Dosage form:	Injection (IV infusion); FS118 drug product is a sterile, unpreserved, colourless or pale yellow, clear liquid in a single-use vial.
Composition:	FS118 =15.000 mg/ml In House Specification Active
Indications:	Advanced and Early-Stage Malignancies

Annexure:

Details of clinical trial site:

S. No.	Name and address of clinical trial site	Ethics Committee Details	Name of Investigator
1.	Room No. 313, Third Main OPD building, Dept. of Medical Oncology VMMC & Safdarjung Hospital, New Delhi-110029	Institutional Ethics Committee, Room No. 516, 5 th Floor, Main OPD Building, VMMC & Safdarjung Hospital, New Delhi-110029	Dr. Kaushhal Kalra
2.	Daycare Angels under AOH, 3rd floor, Sushrut Hospital & Research Centre, 365, Swastik Park, Chembur (East), Mumbai-400071	Mumbai Oncocare Centre Institutional Ethics Committee, Cellcure Cancer Centre Private Limited, 1 to 4, 1st Floor, Shreepati Arcade, August Kranti Marg, Nana Chowk, Mumbai-400036	Dr. Sangeeta Jiwatani
3.	Tata Medical Center, 14-Mar (EW), New Town, Rajarhat, Kolkata-700160, West Bengal	Institutional Review Board, Tata Medical Center, 14-Mar (EW), New Town, Rajarhat, Kolkata-700160, West Bengal	Dr. Bivas Biswas
4.	Healthcare Global Enterprises Limited, HCG Towers, #8, P Kalinga Rao Road, S R Nagar, Bangalore-560027	HCG - Central Ethics Committee HCG Towers, #8, P Kalinga Rao Road, SR Nagar, Bangalore-560027	Dr. Shekar Patil
